Welcome to our dedicated page for Harmony Biosciences Holdings SEC filings (Ticker: HRMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. Harmony Biosciences is a commercial-stage pharmaceutical company focused on rare neurological diseases, and its filings offer detailed insight into financial performance, clinical milestones and strategic developments around its WAKIX (pitolisant) franchise and late-stage CNS pipeline.
Recent Forms 8-K filed by Harmony Biosciences report preliminary and actual financial results, such as net product revenue for WAKIX, multi-quarter revenue growth and updated annual guidance ranges. These filings also incorporate press releases and investor presentations that describe the company’s status as a profitable, self-funding biotech with a robust late-stage pipeline, as well as disclosures tied to participation in major healthcare conferences. For investors analyzing HRMY, these documents help contextualize revenue trends, cash generation and spending on research and development, sales and marketing, and general and administrative activities.
Harmony’s 8-K filings also reference significant clinical and regulatory events, including topline data from the Phase 3 RECONNECT study of ZYN002 in Fragile X syndrome, preannounced WAKIX performance, and updates on Phase 3 and Phase 1 programs such as pitolisant GR, pitolisant HD, EPX-100, EPX-200 and BP1.15205. Through these filings, readers can follow how clinical outcomes, trial initiations and program decisions feed into the company’s overall strategy in sleep–wake disorders, rare epilepsies and neurobehavioral conditions.
On Stock Titan, Harmony Biosciences’ SEC filings are complemented by AI-powered summaries that explain the key points of lengthy documents, including 8-Ks and, when available, 10-K annual reports, 10-Q quarterly reports and proxy materials. Investors can also monitor insider and executive transaction reports on Form 4 and other ownership filings as they appear in the EDGAR feed. This combination of real-time updates and AI-generated explanations helps users quickly understand the implications of HRMY’s regulatory disclosures without reading every page of each filing.
Harmony Biosciences (HRMY) filed an 8-K announcing it furnished a press release with financial results for the quarter ended September 30, 2025 and posted an updated investor presentation. The materials are included as Exhibits 99.1 and 99.2 and are provided under Regulation FD.
The company states these exhibits are furnished and not deemed filed under Section 18 of the Exchange Act, and may be used in presentations to investors and analysts. Forward‑looking statements are subject to the risk factors described in prior SEC filings.
Harmony Biosciences (HRMY) announced preliminary net product revenue for the third quarter of 2025 and updated its 2025 net product revenue guidance. The company furnished these details in a press release attached as Exhibit 99.1.
The disclosure falls under Results of Operations and Financial Condition and includes standard forward‑looking statement language.
Sandip Kapadia, Chief Financial Officer of Harmony Biosciences Holdings, Inc. (HRMY), reported transactions dated 09/30/2025. He acquired 45,000 shares upon vesting of restricted stock units (RSUs) granted on 10/04/2023, and a portion of those shares were withheld to satisfy income tax withholdings as noted. Separately, he disposed of 24,039 shares at a price of $27.56 per share, leaving him with 20,961 shares beneficially owned after the sale. The RSUs vest on a schedule: 40% vested on 09/30/2024, and 30% vest on each of 09/30/2025 and 09/30/2026. The filing was signed by an attorney-in-fact on 10/02/2025.
Harmony Biosciences Holdings, Inc. reported new clinical data from its phase 3 registrational RECONNECT study. The company announced topline results showing that the trial did not meet its primary endpoint, which was based on improvement in social avoidance. According to the company, this outcome was primarily due to a higher than expected placebo response rate, which reduced the measured difference between treatment and placebo groups.
The company furnished a detailed press release with the topline results as an exhibit to this report. The disclosure is provided under Regulation FD, meaning Harmony is sharing this information broadly with the market at the same time.
Harmony Biosciences (HRMY) Form 4: Valor IV Pharma Holdings, LLC reported an in-kind pro rata distribution on 08/28/2025 that disposed of 6,618,033 shares of Harmony common stock without consideration, leaving 0 shares directly owned by Valor IV Pharma Holdings following that transaction. The filing lists remaining indirect holdings across related Valor entities and individuals totaling specific lots of 29,497, 437,619, 50,423, 38,275 and 23,714 shares, held by Valor Management L.P., Antonio Gracias, AJG Growth Fund LLC, Juan Sabater and Tamal, LLC, respectively. The distribution is described in footnotes as an in-kind pro rata distribution by Valor IV Pharma Holdings, LLC, without consideration. The filing is signed by Valor principals and by directors Antonio Gracias and Juan A. Sabater on 09/02/2025.
Sandip Kapadia, Chief Financial Officer of Harmony Biosciences Holdings, Inc. (HRMY), sold 21,573 shares of the company's common stock on 08/15/2025 under a Rule 10b5-1 trading plan. The transactions were executed at a weighted average price of $36.4983 per share, with individual sale prices ranging from $36.11 to $36.87. After these dispositions, the Form 4 reports 0 shares beneficially owned by the reporting person. The filing notes the sale was made pursuant to an established trading plan and offers to provide, upon request, the number of shares sold at each price within the disclosed range.
Harmony Biosciences Holdings, Inc. (HRMY) filed a Form 144 reporting a proposed sale of 21,573 common shares, representing restricted stock units acquired on 03/29/2023. The sale is to be executed through Morgan Stanley Smith Barney LLC with an approximate aggregate market value of $787,630.23 and an indicated approximate sale date of 08/15/2025. The filing shows 57,532,601 shares outstanding and indicates no securities sold by the filer in the past three months. The filer certifies they are not aware of undisclosed material adverse information and discloses the sale is related to previously granted RSUs.